von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. - Wikidata - wikimedia - TriplyDB

von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

http://www.wikidata.org/entity/Q37381709

about

Animal models for thrombotic thrombocytopenic purpura Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'Emerging roles for platelets as immune and inflammatory cells Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice Targeting von Willebrand factor and platelet glycoprotein Ib receptor.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.ADAMTS13 and von Willebrand factor interactions.Regulation of VWF expression, and secretion in health and disease.Thrombosis: tangled up in NETs.Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.Remote ischemic perconditioning is effective after embolic stroke in ovariectomized female mice.von Willebrand factor: an emerging target in stroke therapy.von Willebrand factor, Jedi knight of the bloodstream SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in thrombosis and ischemic stroke in mice.The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis.Platelet glycoprotein Ibα is an important mediator of ischemic stroke in mice.Transient ischemic attacks characterized by RNA profiles in blood.How platelets safeguard vascular integrity.Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia.ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model.Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.Extracellular chromatin is an important mediator of ischemic stroke in mice.Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis.Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation.Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13 Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study Structure-function and regulation of ADAMTS-13 protease.The role of ADAMTS13 in acute myocardial infarction: cause or consequence?ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage.VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.Cell biology of ischemia/reperfusion injury.Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.ADAMTS13, TTP and Beyond

P2860

Q26851228-E175A3B9-0AFE-4320-8897-EC053BF99508 Q26865345-E2792B0A-6E2E-497E-98B1-2F74DB402528 Q27016553-3DA0CFF9-42E6-4810-B7C0-A749BAF7B930 Q30504401-F53E4173-52E3-4CD9-B244-00F75BD9555F Q30511960-A1AB88F0-5909-4080-86B8-3EA5D7A718C9 Q33392975-88B6B5D1-01AA-4AEB-AF29-6B001242F21E Q33423350-6289A771-1281-4F2C-94AC-DA650744ECA4 Q33424570-EE8300B3-F2BC-4BDD-92BC-FED462B8E1AC Q33429209-D866EF1F-5C9F-4820-B7A6-8ADE02A6E516 Q33556910-DBD65581-62DA-404B-9518-F86AC3A3C231 Q33773324-920F997C-3AEA-4128-A142-8D049F7044D5 Q33883043-EFDD3043-A9B7-49B9-83B4-9D0129304976 Q33883134-500F7FCD-C864-45D0-B046-35D0982D42A1 Q33915674-B80CC2D8-97B6-4A5E-A1AE-998CB97A29BB Q34106824-1C6A77DD-DC62-4D71-B4EB-9B14BE3F5A03 Q34802412-AD608ADE-E8CC-41D7-BE14-9B9A4D2FD318 Q35197446-7846F9F3-007D-41C9-BAA1-3E29EAA5A606 Q35232725-2A547AAC-2C52-4171-912F-697B087A8FB1 Q35529958-042C4DBD-CB8B-4DBB-864F-36E15750B939 Q35588157-5953F7E7-5C3A-4825-93B2-B0B1E35AD5AB Q35779980-0B07D9A6-5DFF-4E72-BBC1-4BBC073A374B Q35866882-3DF782AA-C16E-431C-A23F-40489B6A0FD1 Q36166160-CD1CC8A1-B64A-4648-9E1E-BC8BCE6A9AD8 Q36174498-3742C377-3FF4-49FE-B01C-7B77F74AA9A6 Q36294654-1135FFA8-DB87-4FDC-A429-6B3A761FE9F5 Q36387981-B6181658-3F88-4C30-B3A4-23B4AF66B0E5 Q36509653-98C75AFB-DBE7-4D71-B465-5A373CB27479 Q36509659-033ABF05-D443-4557-8525-AFA508C85ADA Q36579398-0F0A13EC-1005-45C1-BEB0-464B7ED7426B Q36675073-7CDE72FF-2C08-47DE-BA76-445E60DFB46A Q36903087-45FB0C08-8FD4-437A-9F48-0265F9F7F1A2 Q36990628-A025AC7B-2832-4682-84FA-2C6479E3DB42 Q37019574-9719D59C-6B5F-4B17-857A-DF16CE68DEE1 Q37118505-560F90B0-A2DD-448F-B254-A28866B397CC Q37193285-9063A4C2-4330-4EFA-AC94-62967B8E3A97 Q37366918-2CD76CB9-1A12-4361-B468-D8BBE09FE89D Q37429699-B72D4956-57CF-48FB-944B-D121C1741F2B Q37524901-5480B4FC-120D-4192-BC10-2B5F5CC2E82D Q37671400-E19812B5-3617-40D2-A416-B1FC2DB99120 Q37725685-37117676-656B-4515-AD98-8E18FDAF2234

P2860

von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

http://www.wikidata.org/entity/Q37381709

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

von Willebrand factor-cleaving ...... injury in experimental stroke.

@en

von Willebrand factor-cleaving ...... injury in experimental stroke.

@nl

type

label

von Willebrand factor-cleaving ...... injury in experimental stroke.

@en

von Willebrand factor-cleaving ...... injury in experimental stroke.

@nl

prefLabel

von Willebrand factor-cleaving ...... injury in experimental stroke.

@en

von Willebrand factor-cleaving ...... injury in experimental stroke.

@nl

P1433

Q37381709-16351C13-1C78-45FE-BD14-AD4764D09451

P1476

Q37381709-5597C0CE-981F-49AF-94E0-2B7CC8CE180B

P2093

Q37381709-2DB5DC79-9356-4302-A1D7-1A9291FB62B6

Q37381709-2DD5D83D-65D4-43A0-9BC7-F9B5C72D3716

Q37381709-30AF4601-9737-446F-B0EF-0BF701E1C45F

Q37381709-3CD31EDE-173A-4EBF-AE14-8DFCC8F7B50E

Q37381709-73AADC56-5CF0-4A18-9402-B86877541B1C

Q37381709-8F1AA37E-ADD9-419E-9272-98FBDE3F3331

Q37381709-C6F736E9-8B2E-4BEB-B198-F6ABF58B50FA

Q37381709-D5B4BE4E-C1CE-4EED-B8F1-AFBD1A8D75D1

P2860

Q37381709-006E538B-736F-49E3-A88A-56AA8D10EC4F

Q37381709-03AD75E3-EBA5-4BC9-8A12-B454E59EE883

Q37381709-04732DE9-8D4C-4DFB-9B91-E2891C7AA721

Q37381709-0BD49A9A-E1AF-44C2-A2EA-E97853EBF2A0

Q37381709-107D1CAA-FD8C-431F-A25E-FC5849B525B2

Q37381709-1160EC89-F796-4B26-AEBD-005CA48D8954

Q37381709-223B94DA-26B9-448D-A989-0FC5ECDC18E3

Q37381709-2F795DD4-B114-449B-A872-CA64170B0334

Q37381709-3B3DA623-4487-4178-85B8-2924E91EBF56

Q37381709-3C0DF8E0-EE85-4C1D-8792-33BB59F442CF

P304

Q37381709-D59F28A6-2FDB-41DD-94AB-3B5DF2D7E9FA

P31

Q37381709-5B5A6BCD-FB7C-4008-9D51-1173CA05ED6E

P356

Q37381709-98F9C51C-F154-4F00-8A1B-7B4D80C790D0

P407

Q37381709-3BB1E9AC-91DE-418C-966F-C8F02EACAB3A

P433

Q37381709-AFE335DA-5C6D-4C9F-BD43-0E4D2D39F39D

P478

Q37381709-36AD7C43-DA68-4B85-A4D3-ACCB87CD4775

P577

Q37381709-D1C3D11F-4131-468B-83AE-6C8C39DBA99B

P5875

Q37381709-853C1C35-DED0-44C1-9ED6-B676461173F0

P698

Q37381709-9CBC9004-6BED-42B7-AB0A-DC17C243CB3B

P932

Q37381709-4B9F5C1D-059C-48A5-A585-6606DB787D42

P356

BLOOD-2009-03-213264

P1433

P1476

von Willebrand factor-cleaving ...... injury in experimental stroke.

@en

P2093

Anil K Chauhan

http://www.w3.org/2001/XMLSchema#string

Bing-Qiao Zhao

http://www.w3.org/2001/XMLSchema#string

Denisa D Wagner

http://www.w3.org/2001/XMLSchema#string

Friedrich Scheiflinger

http://www.w3.org/2001/XMLSchema#string

Ian S Patten

http://www.w3.org/2001/XMLSchema#string

Janie J Yang

http://www.w3.org/2001/XMLSchema#string

Matthias Canault

http://www.w3.org/2001/XMLSchema#string

Michael Dockal

http://www.w3.org/2001/XMLSchema#string

P2860

High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis

Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

Inflammation induces hemorrhage in thrombocytopenia.

Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation

New concepts in von Willebrand disease.

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

P304

3329-3334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-03-213264

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26748574

http://www.w3.org/2001/XMLSchema#string

P698

19687510

http://www.w3.org/2001/XMLSchema#string

P932

2759655

http://www.w3.org/2001/XMLSchema#string